Back to results
US 2008/0187509 A1Published application
Pharmaceutical compositions for the treatment of TNF-alpha related disorders
AssigneeXencor, Inc.
InventorsJohn R. Desjarlais, Paul Michael Steed, Jonathan Zalevsky, David Edmund Szymkowski, David F. Carmichael
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition comprising a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α, a buffer, and a tonicity agent, wherein said composition has a pH from approximately 5.0 to 8.0.
Claims6
A pharmaceutical composition comprising:
- a variant TNF-α protein that inhibits the activity of soluble TNF-α while substantially maintaining the activity of transmembrane TNF-α comprising an amino acid sequence corresponding to wild type amino acids 1-157 of Tumor Necrosis FactorAlpha (TNFα) (SEQ ID NO:
- 1) that has at least one amino acid substitution in the Large Domain and at least one amino acid substitution in a domain selected from the group consisting of the DE Loop and the Small Domain, wherein the Large Domain substitution is at a position selected from the group consisting of 21, 30, 31, 32, 33, 35, 65, 66, 67,111, 112, 115, 140, 143, 144, 145 and 146, wherein the Small Domain substitution at a position selected from the group consisting of 75 and 97, wherein the DE Loon substitution at a position selected from the group consisting of 84, 86, 87 and 91;
- a buffer;
- and, a tonicity agent;
- wherein said composition has a pH from approximately 5.0 to 8.0.
2 more elements
Dependencies are inferred from the claim text.